InvestorsHub Logo
Followers 60
Posts 7391
Boards Moderated 0
Alias Born 10/20/2014

Re: raistthemage post# 299544

Wednesday, 09/16/2020 6:44:57 PM

Wednesday, September 16, 2020 6:44:57 PM

Post# of 426070
raisetheimage, BP is in the best position to turn Vascepa into a
Mega-Blockbuster drug. If not in the US, then certainly in Europe.
Who do you think would have a better chance...a BP with decades of
experience with seasoned sales reps who know the ropes? Or JT's
creating yet another expensive sales force? The sooner BP owns this
the more likely it will be that they can lock up feed-stock to prevent
generics from buying in bulk. Vascepa is a great drug which JT has
managed to lay to waste in the US...and you want him to figure out
Europe? JT sounds like a child with a childs mentality when he talks.
Get him to either sell the company for a reasonable price...or go away.
Certainly the BOD could hire someone much more appealing to be the
mouthpiece for AMRN as well as to find a buyer for the company.
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent AMRN News